AbCellera Biologics Inc.
ABCLNASDAQHealthcare● Active
$5.42
$-0.20(-3.56%)
Market Cap$1.7B
P/E Ratio—
52W High$6.79
52W Low$2.525
AbCellera Biologics Inc. (ABCL) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABCL · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($146.41M) | ($162.86M) | ($146.40M) | $158.52M | $153.46M |
| Depreciation & Amort. | $22.17M | $97.00M | $30.89M | $33.10M | $17.25M |
| Stock-Based Comp. | $55.79M | $67.58M | $64.18M | $49.48M | $30.65M |
| Change in Working Capital | ($70.69M) | ($25.84M) | $13.22M | $29.82M | $41.67M |
| Net Cash from Operations | ($131.29M) | ($108.56M) | ($43.88M) | $277.36M | $244.58M |
| Investing Activities | |||||
| Capital Expenditure | ($42.77M) | ($78.40M) | ($77.51M) | ($72.66M) | ($58.45M) |
| Purchases of Investments | ($436.04M) | ($765.09M) | ($1066.16M) | ($781.35M) | ($322.57M) |
| Sales of Investments | $0.00M | $948.81M | $910.94M | $510.63M | $27.61M |
| Net Cash from Investing | $87.75M | $121.41M | ($221.11M) | ($352.63M) | ($332.25M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $13.50M | $11.59M | $2.75M | ($0.95M) |
| Net Cash from Financing | $14.08M | $12.77M | $10.36M | ($1.63M) | ($3.89M) |
| Free Cash Flow | |||||
| Free Cash Flow | ($174.07M) | ($186.95M) | ($121.38M) | $204.70M | $186.13M |
| FCF Margin %(computed) | -231.69% | -648.40% | -319.22% | 42.17% | 49.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more AbCellera Biologics Inc. data
About AbCellera Biologics Inc. (ABCL) Cash Flow Statement
AbCellera Biologics Inc. generated operating cash flow of ($0.13B) and free cash flow of ($0.17B) for 2025 — a FCF margin of -231.69%. Capital expenditure was ($0.04B).
Frequently asked questions
ABCL · 4 questionsAbCellera Biologics Inc. generated free cash flow of ($0.17B) for 2025, up 6.9% year-over-year.
ABCL free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10